These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18668536)

  • 1. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
    Distler JH; Manger B; Spriewald BM; Schett G; Distler O
    Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J; High WA
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
    Daniels CE; Lasky JA; Limper AH; Mieras K; Gabor E; Schroeder DR;
    Am J Respir Crit Care Med; 2010 Mar; 181(6):604-10. PubMed ID: 20007927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib as a novel therapeutic approach for fibrotic disorders.
    Distler JH; Distler O
    Rheumatology (Oxford); 2009 Jan; 48(1):2-4. PubMed ID: 19029132
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.
    Foringer JR; Verani RR; Tjia VM; Finkel KW; Samuels JA; Guntupalli JS
    Ann Pharmacother; 2005 Dec; 39(12):2136-8. PubMed ID: 16288076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
    Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
    Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
    [No Abstract]   [Full Text] [Related]  

  • 12. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
    Porta C; Mutti L; Tassi G
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):149-50. PubMed ID: 16636799
    [No Abstract]   [Full Text] [Related]  

  • 13. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.
    Eklund KK; Lindstedt K; Sandler C; Kovanen PT; Laasonen L; Juurikivi A; Wolff H; Mykkänen M; Joensuu H
    J Clin Rheumatol; 2008 Oct; 14(5):294-6. PubMed ID: 18824923
    [No Abstract]   [Full Text] [Related]  

  • 14. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Cohen MH; Farrell A; Justice R; Pazdur R
    Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
    Silver RT
    Curr Hematol Rep; 2005 May; 4(3):235-7. PubMed ID: 15865878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
    ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
    Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
    Jais X; Launay D; Yaici A; Le Pavec J; Tchérakian C; Sitbon O; Simonneau G; Humbert M
    Arthritis Rheum; 2008 Feb; 58(2):521-31. PubMed ID: 18240255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice.
    Bizario JC; Cerri DG; Rodrigues LC; Oliveira GL; Nomizo A; de Araujo DD; Fukuhara PS; Ribeiro JC; de Castro FA; Costa MC
    J Neuroimmunol; 2009 Jul; 212(1-2):93-101. PubMed ID: 19508953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.